Navigation Links
ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
Date:5/20/2010

TUSTIN, Calif., May 20, 2010 -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine (PS)-targeting antibody bavituximab for the treatment of solid tumors. PS-targeting antibodies represent an entirely new approach to treating cancer, using a novel immunomodulatory mechanism that enables the patient's own immune system to attack and destroy the tumor. Phase II data on the company's lead PS-targeting antibody bavituximab administered in combination with chemotherapy will be presented at the 2010 ASCO Annual Meeting.

"PS is a highly immunosuppressive molecule that inactivates the immune system and allows tumors to evade detection," commented Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center, a scientific advisor to Peregrine and a pioneer in the development of PS-targeting therapies. "Supported by a growing body of research, PS-targeting antibodies appear to play a critical role in blocking this immunosuppressive molecule and reactivating the immune system's ability to mount a robust anti-tumor response. Since chemotherapy increases the exposure of PS on tumor blood vessels, bavituximab has even more of this immunosuppressive molecule to target, potentially offering a new synergistic approach for the treatment of cancer."

Based on the positive data reported to date, Peregrine plans to initiate a new randomized, placebo-controlled, double-blinded Phase II trial of bavituximab in combination with chemotherapy in refractory non-small cell lung cancer (NSCLC) patients. A new Phase II trial in front-line NSCLC patients is also expected to begin in by mid-year.

Reactivating the Immune System by Blocking "Flipped" Phospholipids


'/>"/>
Contact: Barbara Lindheim
blindheim@biocompartners.com
212-918-4650
BioCom Partners
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. TCT for Surgeons course will highlight hybrid surgical and interventional techniques
2. Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010
3. Health: Stem Cell Breakthrough Highlights Adult Stem Cell Promise Says Christian Drapeau
4. St. Vincent's Hospital Layoffs Highlight Need for WARN Notice and Remedies
5. Professional Members of Human Rights Organization Hold Press Conference to Highlight Government Invasion of Privacy
6. CCH Briefing Highlights Employer, Medicare Provisions of Health Care Reform Proposals
7. Special Session Highlights Late-Breaking Abstracts
8. DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2009 Financial Results and Corporate Highlights Conference Call
9. Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns
10. FDA Cancer Drug Approval Rate Highlighted in JNCI
11. New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... & Caicos Islands, BWI (PRWEB) , ... July 31, 2015 , ... The Venetian on ... for fall, 2015. Guests who stay at the Venetian will save 40% on their ... The fall months are always quiet in the Turks & Caicos, providing a chance to ...
(Date:7/30/2015)... ... 30, 2015 , ... The Clinical Data Interchange Standards Consortium ... announce that data standards for clinical research in the areas of Schizophrenia, Hepatitis ... . These three Therapeutic Area (TA) standards were developed per the CDISC global, ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will ... site. As discussed in a June 8, 2015 article published by Nasdaq , ... have been caused by its computer-driven cars, which such industry players as Tesla CEO ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... “Beachside Nursing Center,” to announce its position as one of Medicare’s top-rated ... and staff members support the CMS rating system, which monitors health inspections, ...
Breaking Medicine News(10 mins):Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2
... patients would bear the brunt of a Government proposal to ... ,This plan would very likely push up the ... to pay for their medication facing a greater financial burden, ... it ensures that Australians are able to access the ...
... avian influenza since 2005, state media said Friday. ... a 29-year-old man has been infected with the deadly H5N1 ... to Vietnam News Agency. ,The man, from Vinh ... from high fever and breathing difficulties on May 10. He ...
... improve global public health, Weill Cornell Medical College students ... the World Health Organization's (WHO) list of essential ... to choose which high-priority drugs should be supplied to ... chapter of Universities Allied for Essential Medicines (UAEM) answered ...
... that they have identified a gene that needs to be ... ,The gene detected by the researchers ... of the well-known breast cancer gene BRCA1. ,The ... of the University of Pennsylvania and the Dana-Farber Cancer Institute, ...
... that appetite-regulating peptides leptin and ghrelin influence alcohol cravings ... powerful urge to drink, is an important contributor to ... Otto Lesch of the University of Vienna has divided ... that refers to people with heavy alcohol withdrawals who ...
... has opened one of the few clinics in the ... Down Syndrome. Because of improvements in diagnosis, treatment ... patients are now routinely living into adulthood, and have ... of the population. ,Childrens hospitals, pediatricians and our ...
Cached Medicine News:Health News:Medical College Students Help Change Global Health Policy 2Health News:Scientists Identify New Breast Cancer Gene 2Health News:Appetite-regulating Peptides Influence Alcohol Cravings 2Health News:Adult Down Syndrome Clinic Opened at UAB 2
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 29, 2011 Professional and Trade Relations groups play ... to professional, payer and patient groups. However, today,s restrictive ... PTR activities - thus creating pressure on PTR groups ... optimize their impact.   Recognizing changing needs ...
... April 29, 2011 Phil Hagerman, president and CEO of ... Leader & Innovator of the Year. The award ... which co-sponsors the annual award along with Grant Thornton LLP, ... and Technology Report. Hagerman was chosen from among 45 nominees ...
Cached Medicine Technology:Professional Relations Excellence Outlined in New Best Practices, LLC Report 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 2Diplomat Specialty Pharmacy's Hagerman Named Grant Thornton Leader & Innovator of the Year 3
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: